# Apatinib Combined With Radiotherapy in Patient With BM From Drive Gene Negative NSCLC

> **NCT03801200** · PHASE2 · UNKNOWN · sponsor: **Hubei Cancer Hospital** · enrollment: 90 (estimated)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** Apatinib

## Key facts

- **NCT ID:** NCT03801200
- **Lead sponsor:** Hubei Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09-10
- **Primary completion:** 2021-09-10
- **Final completion:** 2023-09-10
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2022-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03801200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03801200, "Apatinib Combined With Radiotherapy in Patient With BM From Drive Gene Negative NSCLC". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03801200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*